In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis
about
Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitroEfficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model.Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography.Recent progress in novel macrolides, quinolones, and 2-pyridones to overcome bacterial resistance.In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae.In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumoniaStreptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux systemComparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes.Efficacy of trovafloxacin for treatment of experimental Bacteroides infection in young and senescent mice.Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infectionsIn vivo bioluminescence imaging to evaluate systemic and topical antibiotics against community-acquired methicillin-resistant Staphylococcus aureus-infected skin wounds in mice.Trovafloxacin: a new fluoroquinolone.Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.Effect of zinc-reversible growth-inhibitory activity in human empyema fluid on antibiotic microbicidal activityA new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilitiesComparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus.Uptake and intracellular activity of trovafloxacin in human phagocytes and tissue-cultured epithelial cells.In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.Synergistic activity of trovafloxacin and ceftriaxone or vancomycin against Streptococcus pneumoniae with various penicillin susceptibilities.Protective effect of trovafloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in a murine sepsis model.Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha.
P2860
Q24673222-E70AB7A8-E282-4184-9650-B113E2022BDBQ33689451-452A75C7-E7FB-46DD-96FC-051CC519F84CQ33692694-49AE4EA7-3B13-44F6-9936-5C48D58DB1C9Q33695030-2D033CA1-2552-4C2B-B81A-30A7E60909C4Q33771929-323812F9-FD3E-4DAE-9512-43CBCC887F97Q33976279-1B1F8C52-369F-434E-858F-3C8941262C2CQ33982034-8457A0B2-2518-4D94-820F-F70E7A3D4D96Q35122254-6B2AA1A7-6DC3-44CC-8529-40C635A76D1FQ35125999-57350EBB-47C4-407A-9FC4-D2475E63171CQ35133082-D11A6A61-5F0F-4EF9-9FD4-FE50B593A325Q35138053-0522E02A-1E3E-43AB-B6CA-226012BF7171Q35138694-CE478237-9CA2-47BE-9CA7-985F1832D085Q36558524-9143CC7F-6A93-48DE-95AD-24562EF6AF76Q37879173-DE060079-53A5-403F-93B2-FBEC0A6F57BFQ39469535-4B959E96-D015-4A25-A960-066B0193FF6EQ39472617-BF611C07-72C4-4421-8D48-8DA0D3AA3F9AQ39559370-B2B351B6-7B72-4E30-8B4B-A78D3A9E3E40Q39559768-7FA99BC5-A715-4830-A85D-5C8FE2234DFAQ39783596-2C4771D5-431D-4AE2-8DF7-AF59A8E9A224Q39783790-2FE1B7A6-5D78-4390-9C8E-13C07B9869C2Q42743245-9A491DDA-5E55-45E5-A585-DC88772E52CDQ44284142-B36F49AE-C621-4309-9A98-6750A1175B65Q54435973-A6DFF20A-B89C-4388-83D0-EF1075E5B726
P2860
In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis
description
1995 nî lūn-bûn
@nan
1995 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
In vivo efficacy of trovafloxa ...... niae, and Bacteroides fragilis
@ast
In vivo efficacy of trovafloxa ...... niae, and Bacteroides fragilis
@en
In vivo efficacy of trovafloxa ...... niae, and Bacteroides fragilis
@nl
type
label
In vivo efficacy of trovafloxa ...... niae, and Bacteroides fragilis
@ast
In vivo efficacy of trovafloxa ...... niae, and Bacteroides fragilis
@en
In vivo efficacy of trovafloxa ...... niae, and Bacteroides fragilis
@nl
prefLabel
In vivo efficacy of trovafloxa ...... niae, and Bacteroides fragilis
@ast
In vivo efficacy of trovafloxa ...... niae, and Bacteroides fragilis
@en
In vivo efficacy of trovafloxa ...... niae, and Bacteroides fragilis
@nl
P2093
P2860
P356
P1476
In vivo efficacy of trovafloxa ...... niae, and Bacteroides fragilis
@en
P2093
Cimochowski CR
Faiella JA
P2860
P304
P356
10.1128/AAC.39.10.2210
P407
P577
1995-10-01T00:00:00Z